Abstract
Today sintering of inflow cannulae in left ventricular assist devices (LVAD) is accepted as standard to ensure good myocardial ingrowth, preventing thrombus formation at the apical penetration site. Various studies like the ADVANCE trial compared the formerly polished pump of the HeartWare HVAD and the sintered version commercialized since 2012, investigating the incidence of pump thrombosis and thromboembolic complications. Though this is of essential clinical importance, it is only a surrogate for inflow cannula thrombus development.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
